Mereo BioPharma Group annual return on equity
2022
2023
2024
2025
Mereo BioPharma Group Return on Equity (ROE) Growth & History (MREO)
Mereo BioPharma Group's return on equity was −82.21% for fiscal 2025.
View full Mereo BioPharma Group company overviewMereo BioPharma Group annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −82.21% | −4.63 pp |
| 2024 | 2024-12-31 | −77.58% | −19.77 pp |
| 2023 | 2023-12-31 | −57.81% | +0.99 pp |
| 2022 | 2022-12-31 | −58.80% | — |
Mereo BioPharma Group quarterly return on equity
Q4.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −22.34% | +3.24 pp |
| Q1 2026 | 2026-03-31 | −17.92% | +3.37 pp |
| Q4 2025 | 2025-12-31 | −16.80% | — |
| Q3 2025 | 2025-09-30 | −13.94% | +476.77 pp |
| Q2 2025 | 2025-06-30 | −25.58% | −5.41 pp |
| Q1 2025 | 2025-03-31 | −21.29% | −2.12 pp |
| Q3 2024 | 2024-09-30 | −490.71% | — |
| Q2 2024 | 2024-06-30 | −20.17% | — |
| Q1 2024 | 2024-03-31 | −19.17% | — |
| Q4 2023 | 2023-12-31 | −17.87% | — |
Mereo BioPharma Group return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, Mereo BioPharma Group's return on equity decreased from −58.80% to −82.21%, a change of −23.40 percentage points. The latest reported quarter, Q2 2026, shows −22.34%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mereo BioPharma Group source filings ↗